Pulmonary hypertension in dogs: Diagnosis and therapy

Veterinary Clinics of North America - Small Animal Practice

Volumn 40, Issue 4, 2010, Pages 623-641

  Kellihan, Heidi B ^a   Stepien, Rebecca L ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Echocardiographic; Heart disease; Pulmonary disease; Right heart catheterization; Sildenafil; Syncope

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ARGININE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM SENSITIZER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; HYDRALAZINE; ILOPROST; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PIMOBENDAN; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; TADALAFIL; THEOPHYLLINE; UNIPROST; VARDENAFIL;

ARTERY BLOOD FLOW; CARDIOVASCULAR PARAMETERS; CLINICAL FEATURE; CONTINUOUS INFUSION; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DOG DISEASE; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HEART CATHETERIZATION; HEART PERFORMANCE; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; LONGEVITY; LUNG INSUFFICIENCY; NONHUMAN; PHYSICAL EXAMINATION; PROGNOSIS; PROTEIN ANALYSIS; PULMONARY ARTERY; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SURVIVAL TIME; SYSTOLIC TIME INTERVAL; TEI INDEX; THORAX RADIOGRAPHY; TISSUE DOPPLER IMAGING; TREATMENT RESPONSE; TRICUSPID VALVE REGURGITATION; TWO DIMENSIONAL ECHOCARDIOGRAPHY; VETERINARY MEDICINE; ANIMAL; DOG; DOG DISEASES; FEMALE; HYPERTENSION, PULMONARY; MALE; TREATMENT OUTCOME; VETERINARY;

CANIS FAMILIARIS; SYNCOPE;

ANIMALS; CARDIAC CATHETERIZATION; DOG DISEASES; DOGS; ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HYPERTENSION, PULMONARY; MALE; PROGNOSIS; TREATMENT OUTCOME;

EID: 77954046312     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2010.03.011     Document Type: Review

References (96)

1. Kellum H.B., Stepien R.L. Sildenafil citrate therapy in 22 dogs with pulmonary hypertension. J Vet Intern Med 2007, 21(6):1258-1264.
2. Fleming E. Pulmonary hypertension. Compend Contin Educ Vet 2006, 28:720-730.
3. Johnson L., Boon J., Orton E.C. Clinical characteristics of 53 dogs with Doppler-derived evidence of pulmonary hypertension: 1992-1996. J Vet Intern Med 1999, 13(5):440-447.
4. Bach J.F., Rozanski E.A., MacGregor J., et al. Retrospective evaluation of sildenafil citrate as a therapy for pulmonary hypertension in dogs. J Vet Intern Med 2006, 20(5):1132-1135.
5. Schober K.E., Baade H. Doppler echocardiographic prediction of pulmonary hypertension in West Highland white terriers with chronic pulmonary disease. J Vet Intern Med 2006, 20(4):912-920.
6. Pyle R.L., Abbott J., MacLean H. Pulmonary hypertension and cardiovascular sequelae in 54 dogs. Int J Appl Res Vet Med 2004, 2(2):99.
7. Simonneau G., Galie N., Rubin L.J., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004, 43(12 Suppl S):5S-12S.
8. Stepien R.L. Pulmonary arterial hypertension secondary to chronic left-sided cardiac dysfunction in dogs. J Small Anim Pract 2009, 50(Suppl 1):34-43.
9. LaRue M.J., Murtaugh R.J. Pulmonary thromboembolism in dogs: 47 cases (1986-1987). J Am Vet Med Assoc 1990, 197(10):1368-1372.
10. Johnson L.R., Lappin M.R., Baker D.C. Pulmonary thromboembolism in 29 dogs: 1985-1995. J Vet Intern Med 1999, 13(4):338-345.
11. Norris C.R., Griffey S.M., Samii V.F. Pulmonary thromboembolism in cats: 29 cases (1987-1997). J Am Vet Med Assoc 1999, 215(11):1650-1654.
12. Zabka T.S., Campbell F.E., Wilson D.W. Pulmonary arteriopathy and idiopathic pulmonary arterial hypertension in six dogs. Vet Pathol 2006, 43(4):510-522.
13. Serres F., Chetboul V., Gouni V., et al. Diagnostic value of echo-Doppler and tissue Doppler imaging in dogs with pulmonary arterial hypertension. J Vet Intern Med 2007, 21(6):1280-1289.
14. Serres F.J., Chetboul V., Tissier R., et al. Doppler echocardiography-derived evidence of pulmonary arterial hypertension in dogs with degenerative mitral valve disease: 86 cases (2001-2005). J Am Vet Med Assoc 2006, 229(11):1772-1778.
15. Sasaki Y., Kitagawa H., Hirano Y. Relationship between pulmonary arterial pressure and lesions in the pulmonary arteries and parenchyma, and cardiac valves in canine dirofilariasis. J Vet Med Sci 1992, 54(4):739-744.
16. Russell N.J., Irwin P.J., Hopper B.J., et al. Acute necrotising pulmonary vasculitis and pulmonary hypertension in a juvenile dog. J Small Anim Pract 2008, 49(7):349-355.
17. Rawlings C.A., Farrell R.L., Mahood R.M. Morphologic changes in the lungs of cats experimentally infected with dirofilaria immitis. Response to aspirin. J Vet Intern Med 1990, 4(6):292-300.
18. Rawlings C.A., Tackett R.L. Postadulticide pulmonary hypertension of canine heartworm disease: successful treatment with oxygen and failure of antihistamines. Am J Vet Res 1990, 51(10):1565-1569.
19. Pyle R.L., Park R.D., Alexander A.F., et al. Patent ductus arteriosus with pulmonary hypertension in the dog. J Am Vet Med Assoc 1981, 178(6):565-571.
20. Oswald G.P., Orton E.C. Patent ductus arteriosus and pulmonary hypertension in related Pembroke Welsh corgis. J Am Vet Med Assoc 1993, 202(5):761-764.
21. Mitchell C.W. The imaging diagnosis of pulmonary thromboembolism. Can Vet J 2009, 50(2):199-202.
22. Johnson L. Diagnosis of pulmonary hypertension. Clin Tech Small Anim Pract 1999, 14(4):231-236.
23. Hirano Y., Kitagawa H., Sasaki Y. Relationship between pulmonary arterial pressure and pulmonary thromboembolism associated with dead worms in canine heartworm disease. J Vet Med Sci 1992, 54(5):897-904.
24. Grover R.F., Johnson R.L., McCullough R.G., et al. Pulmonary hypertension and pulmonary vascular reactivity in beagles at high altitude. J Appl Physiol 1988, 65(6):2632-2640.
25. Glaus T.M., Soldati G., Maurer R., et al. Clinical and pathological characterisation of primary pulmonary hypertension in a dog. Vet Rec 2004, 154(25):786-789.
26. Glaus T.M., Tomsa K., Hassig M., et al. Echocardiographic changes induced by moderate to marked hypobaric hypoxia in dogs. Vet Radiol Ultrasound 2004, 45(3):233-237.
27. Glaus T.M., Hassig M., Baumgartner C., et al. Pulmonary hypertension induced in dogs by hypoxia at different high-altitude levels. Vet Res Commun 2003, 27(8):661-670.
28. Glaus T.M., Hauser K., Hassig M., et al. Non-invasive measurement of the cardiovascular effects of chronic hypoxaemia on dogs living at moderately high altitude. Vet Rec 2003, 152(26):800-803.
29. Glaus T.M., Grenacher B., Koch D., et al. High altitude training of dogs results in elevated erythropoietin and endothelin-1 serum levels. Comp Biochem Physiol A Mol Integr Physiol 2004, 138(3):355-361.
30. Gavaghan B.J., Lapointe J.M., Thomas W.P. Acute onset of pulmonary necrotising arteritis in a dog with a left-to-right patent ductus arteriosus. Aust Vet J 1998, 76(12):786-791.
31. Cote E., Ettinger S.J. Long-term clinical management of right-to-left (" reversed" ) patent ductus arteriosus in 3 dogs. J Vet Intern Med 2001, 15(1):39-42.
32. Chiavegato D., Borgarelli M., D'Agnolo G., et al. Pulmonary hypertension in dogs with mitral regurgitation attributable to myxomatous valve disease. Vet Radiol Ultrasound 2009, 50(3):253-258.
33. Chetboul V., Serres F., Tissier R., et al. Association of plasma N-terminal pro-B-type natriuretic peptide concentration with mitral regurgitation severity and outcome in dogs with asymptomatic degenerative mitral valve disease. J Vet Intern Med 2009, 23(5):984-994.
34. Borgarelli M., Zini E., D'Agnolo G., et al. Comparison of primary mitral valve disease in German shepherd dogs and in small breeds. J Vet Cardiol 2004, 6(2):27-34.
35. Atkinson K.J., Fine D.M., Thombs L.A., et al. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs. J Vet Intern Med 2009, 23(6):1190-1196.
36. Ware W.B. Multiple congenital cardiac anomalies and Eisenmenger's syndrome in a dog. Compend Contin Educ Vet 1988, 10(8):932.
37. Yuan J.X., Rubin L.J. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation 2005, 111(5):534-538.
38. Corcoran B.M., Cobb M., Martin M.W., et al. Chronic pulmonary disease in West Highland white terriers. Vet Rec 1999, 144(22):611-616.
39. Toyoshima Y., Kanemoto I., Arai S., et al. A case of long-term sildenafil therapy in a young dog with pulmonary hypertension. J Vet Med Sci 2007, 69(10):1073-1075.
40. Chemla D., Castelain V., Herve P., et al. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J 2002, 20(5):1314-1331.
41. Jardin F., Dubourg O., Bourdarias J.P. Echocardiographic pattern of acute cor pulmonale. Chest 1997, 111(1):209-217.
42. Fine D.M., Declue A.E., Reinero C.R. Evaluation of circulating amino terminal-pro-B-type natriuretic peptide concentration in dogs with respiratory distress attributable to congestive heart failure or primary pulmonary disease. J Am Vet Med Assoc 2008, 232(11):1674-1679.
43. Leuchte H.H., El Nounou M., Tuerpe J.C., et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest 2007, 131(2):402-409.
44. Andreassen A.K., Wergeland R., Simonsen S., et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 2006, 98(4):525-529.
45. McLaughlin V.V., Archer S.L., Badesch D.B., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009, 119(16):2250-2294.
46. Yock P.G., Popp R.L. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984, 70(4):657-662.
47. Fisher M.R., Forfia P.R., Chamera E., et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009, 179(7):615-621.
48. Martin-Duran R., Larman M., Trugeda A., et al. Comparison of Doppler-determined elevated pulmonary arterial pressure with pressure measured at cardiac catheterization. Am J Cardiol 1986, 57(10):859-863.
49. Uehara Y. An attempt to estimate the pulmonary artery pressure in dogs by means of pulsed Doppler echocardiography. J Vet Med Sci 1993, 55(2):307-312.
50. Tei C., Dujardin K.S., Hodge D.O., et al. Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr 1996, 9(6):838-847.
51. Baumwart R.D., Meurs K.M., Bonagura J.D. Tei index of myocardial performance applied to the right ventricle in normal dogs. J Vet Intern Med 2005, 19(6):828-832.
52. Yeo T.C., Dujardin K.S., Tei C., et al. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998, 81(9):1157-1161.
53. Champion H.C., Michelakis E.D., Hassoun P.M. Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation 2009, 120(11):992-1007.
54. Farber H.W., Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004, 351(16):1655-1665.
55. Stewart D.J., Levy R.D., Cernacek P., et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?. Ann Intern Med 1991, 114(6):464-469.
56. Rubens C., Ewert R., Halank M., et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001, 120(5):1562-1569.
57. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001, 358(9288):1119-1123.
58. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346(12):896-903.
59. McLaughlin V.V., Sitbon O., Badesch D.B., et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005, 25(2):244-249.
60. Barst R.J., Rich S., Widlitz A., et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002, 121(6):1860-1868.
61. Galie N., Badesch D., Oudiz R., et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005, 46(3):529-535.
62. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med 1996, 334(5):296-302.
63. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347(5):322-329.
64. Laliberte K., Arneson C., Jeffs R., et al. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004, 44(2):209-214.
65. McLaughlin V.V., McGoon M.D. Pulmonary arterial hypertension. Circulation 2006, 114(13):1417-1431.
66. Michelakis E.D., Tymchak W., Noga M., et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003, 108(17):2066-2069.
67. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353(20):2148-2157.
68. Humpl T., Reyes J.T., Holtby H., et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005, 111(24):3274-3280.
69. Ghofrani H.A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002, 360(9337):895-900.
70. Hoeper M.M., Welte T. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2006, 354(10):1091-1093. [author reply: 1091-3].
71. Klinger J.R., Thaker S., Houtchens J., et al. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest 2006, 129(2):417-425.
72. Gan C.T., Holverda S., Marcus J.T., et al. Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients. Chest 2007, 132(1):11-17.
73. van Wolferen S.A., Boonstra A., Marcus J.T., et al. Right ventricular reverse remodeling after sildenafil in pulmonary arterial hypertension. Heart 2006, 92(12):1860-1861.
74. Takimoto E., Champion H.C., Li M., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005, 11(2):214-222.
75. Rondelet B., Kerbaul F., Van Beneden R., et al. Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy. Circulation 2004, 110(15):2220-2225.
76. Borlaug B.A., Melenovsky V., Marhin T., et al. Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation 2005, 112(17):2642-2649.
77. Ghofrani H.A., Voswinckel R., Reichenberger F., et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004, 44(7):1488-1496.
78. Tay E.L., Geok-Mui M.K., Poh-Hoon M.C., et al. Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case series of 12 patients. Int J Cardiol 2008, 125(3):416-417.
79. Pepke-Zaba J., Beardsworth A., Chan M., et al. Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension. Curr Med Res Opin 2009, 25(10):2479-2485.
80. Galie N., Brundage B.H., Ghofrani H.A., et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119(22):2894-2903.
81. Serres F., Nicolle A.P., Tissier R., et al. Efficacy of oral tadalafil, a new long-acting phosphodiesterase-5 inhibitor, for the short-term treatment of pulmonary arterial hypertension in a dog. J Vet Med A Physiol Pathol Clin Med 2006, 53(3):129-133.
82. Jing Z.C., Jiang X., Wu B.X., et al. Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study. Heart 2009, 95(18):1531-1536.
83. Toque H.A., Teixeira C.E., Priviero F.B., et al. Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. Br J Pharmacol 2008, 154(4):787-796.
84. Mehta S., Stewart D.J., Langleben D., et al. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation 1995, 92(6):1539-1545.
85. Fagan J.M., Rex S.E., Hayes-Licitra S.A., et al. L-arginine reduces right heart hypertrophy in hypoxia-induced pulmonary hypertension. Biochem Biophys Res Commun 1999, 254(1):100-103.
86. Howell K., Costello C.M., Sands M., et al. L-arginine promotes angiogenesis in the chronically hypoxic lung: a novel mechanism ameliorating pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2009, 296(6):L1042-L1050.
87. Souza-Costa D.C., Zerbini T., Metzger I.F., et al. L-Arginine attenuates acute pulmonary embolism-induced oxidative stress and pulmonary hypertension. Nitric Oxide 2005, 12(1):9-14.
88. Souza-Silva A.R., Dias-Junior C.A., Uzuelli J.A., et al. Hemodynamic effects of combined sildenafil and L-arginine during acute pulmonary embolism-induced pulmonary hypertension. Eur J Pharmacol 2005, 524(1-3):126-131.
89. Kerbaul F., Gariboldi V., Giorgi R., et al. Effects of levosimendan on acute pulmonary embolism-induced right ventricular failure. Crit Care Med 2007, 35(8):1948-1954.
90. Kerbaul F., Rondelet B., Demester J.P., et al. Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failure. Crit Care Med 2006, 34(11):2814-2819.
91. Nieminen M.S., Akkila J., Hasenfuss G., et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000, 36(6):1903-1912.
92. Fuentes V.L. Use of pimobendan in the management of heart failure. Vet Clin North Am Small Anim Pract 2004, 34(5):1145-1155.
93. Barnes P.J. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003, 167(6):813-818.
94. Johnson L. Patient selection and therapeutics in pulmonary hypertension. The European College of Veterinary Internal Medicine-Companion Animals Congress Proceedings. Amsterdam (The Netherlands), 2006.
95. Matthay R.A. Favorable cardiovascular effects of theophylline in COPD. Chest 1987, 92(1 Suppl):22S-26S.
96. Sitbon O., Humbert M., Jagot J.L., et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998, 12:265.